Argomenti e Notizie
con raccolte
bibliografiche su
PubMed Logo
a cura del
Dott. C.Tarozzi
Anno 22°
Num. 134
Recens. 2627
Aderiamo allo standard HONcode per l'affidabilitŗ dell'informazione medica questo sito aderisce fin dal 2004 allo standard HONcode per l'affidabilità dell'informazione medica. Verifica qui.
Rassegna - Alimenti e Calcio - Questionari - T-Score - Valore di un Test - Calcolatori - Contatti - Digitalia - Radioactivity
Ricerca nell'archivio di questo sito...
Nuova bibliografia selezionata fino al mese di maggio 2017 (recensioni 20) Ordina per Autore - Titolo - Rivista
Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskelet Disord. 2017 Apr 27;18(1):174. doi: 10.1186/s12891-017-1520-6.

Albert SG, Reddy S.
Endocr Pract. 2017 Apr 27. doi: 10.4158/EP161678.RA.

Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG.
Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
Maturitas. 2017 Apr 28. pii: S0378-5122(17)30574-1. doi: 10.1016/j.maturitas.2017.04.019.

Anastasilakis AD, Yavropoulou MP, Makras P.
Bisphosphonates or denosumab discontinuation and risk of fractures.
Maturitas. 2017 Apr 27. pii: S0378-5122(17)30553-4. doi: 10.1016/j.maturitas.2017.04.016.

Body JJ, Gatta F, De Cock E, Tao S, Kritikou P, Wimberger P, Mebis J, Peeters M, Pedrazzoli P, Caraceni A, Adamo V, Hechmati G.
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
Support Care Cancer. 2017 Apr 21. doi: 10.1007/s00520-017-3697-5.

Bover J, Bailone L, López-Báez V, Benito S, Ciceri P, Galassi A, Cozzolino M.
Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
J Nephrol. 2017 Apr 21. doi: 10.1007/s40620-017-0404-z. Review.

Cristino J, Finek J, Jandova P, Kolek M, P√°sztor B, Giannopoulou C, Qian Y, Brezina T, Lothgren M.
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
J Med Econ. 2017 May 9:1-22. doi: 10.1080/13696998.2017.1328423.

Fritzsche H, Schaser KD, Hofbauer C.
[Benign tumours and tumour-like lesions of the bone : General treatment principles].
Orthopade. 2017 Apr 27. doi: 10.1007/s00132-017-3429-z.

Fukumoto S, Matsumoto T.
Recent advances in the management of osteoporosis.
F1000Res. 2017 May 5;6:625. doi: 10.12688/f1000research.10682.1. eCollection 2017. Review.

Kettle JK, Patel PB.
Feasibility of extended dosing intervals of denosumab.
J Oncol Pharm Pract. 2017 Jan 1:1078155217703791. doi: 10.1177/1078155217703791.

Kim SY, Ok HG, Birkenmaier C, Kim KH.
Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Korean J Pain. 2017 Apr;30(2):86-92. doi: 10.3344/kjp.2017.30.2.86. Epub 2017 Mar 31. Review.

Lim SY, Bolster MB.
Profile of romosozumab and its potential in the management of osteoporosis.
Drug Des Devel Ther. 2017 Apr 13;11:1221-1231. doi: 10.2147/DDDT.S127568. eCollection 2017. Review.

Nakamura Y, Suzuki T, Yoshida T, Yamazaki H, Kato H.
Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
Nutrients. 2017 Apr 26;9(5). pii: E428. doi: 10.3390/nu9050428.

Nishimura S, Hashimoto K, Tan A, Yagyu Y, Akagi M.
Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: A case report.
Mol Clin Oncol. 2017 Mar;6(3):307-310. doi: 10.3892/mco.2017.1137.

Qaseem A, Forciea MA, McLean RM, Denberg TD;
Clinical Guidelines Committee of the American College of Physicians Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians.
Ann Intern Med. 2017 May 9. doi: 10.7326/M15-1361.

Reid IR, Horne AM, Mihov B, Gamble GD.
Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
Calcif Tissue Int. 2017 May 13. doi:10.1007/s00223-017-0288-x.

Schröder J, Fietz T, Köhler A, Petersen V, Tesch H, Spring L, Fleitz A, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer)
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Eur J Cancer. 2017 May 8;79:139-148. doi: 10.1016/j.ejca.2017.03.031.

Suzuki T, Nakamura Y, Tanaka M, Kamimura M, Ikegami S, Uchiyama S, Kato H.
Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Mod Rheumatol. 2017 Apr 11:1-4. doi: 10.1080/14397595.2017.1308454.

Tanaka T, Slavin J, McLachlan SA, Choong P.
Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: A case report.
Oncol Lett. 2017 Apr;13(4):2105-2108. doi: 10.3892/ol.2017.5693. Epub 2017 Feb 8.

Thornley P, Habib A, Bozzo A, Evaniew N, Ghert M.
The Role of Denosumab in the Modern Treatment of Giant Cell Tumor of Bone.
JBJS Rev. 2017 Apr 25. doi: 10.2106/JBJS.RVW.16.00072.

(Vers. 2.1)  Modificato il 24-5-2017   
questo sito aderisce ai principi HONCODE    disclaimer